For the first time in almost 50 years, there are two new drugs - delamanid and bedaquiline - available to treat individuals with multidrug-resistant tuberculosis (MDR-TB). This rapid clinical advice document is meant to provide clinical recommendations on their use by providers in the field caring for children. The document builds on the current experience with bedaquiline and delamanid in adult populations, including data from clinical trials, expanded access/compassionate use, and programmatic implementation. It also considers the results of available data from clinical trials on delamanid in children, and the compassionate use of both delamanid and bedaquiline in children and adolescents.
rapid clinical advice tb paeds
Rapid clinical advice on the management of DRTB in children (The Sentinel Project)